HEMOGENYX PHARMACEUTICALS PLC

Regulatory Filings • Nov 12, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0215T

Hemogenyx Pharmaceuticals PLC

12 November 2019

Hemogenyx Pharmaceuticals plc 

("Hemogenyx" or the "Company")

Presentation at the Investival Showcase

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that it will be presenting at the Annual Investival Showcase to be held on November 19, 2019 at Waldorf Hilton Hotel, London.

Dr Vladislav Sandler, Chief Executive Officer, is scheduled to present on Tuesday, November 19 at 2:45 p.m., with one-on-one meetings to be held throughout the conference.

The Investival Showcase (https://www.lsxleaders.com/investival-showcase) continues its exclusive partnership with global investment bank Jefferies, with the showcase co-located with the Jefferies 2019 London Healthcare Conference.  The Investival Showcase directly connects life sciences corporates with global capital.  It offers the opportunity for a greater proportion of private and smaller cap public companies to be a part of the biggest week in European life sciences investment.  It provides the opportunity to pitch, profile and connect with investment partners brought together in London by both LSX, and Jefferies.

Enquiries:

Hemogenyx Pharmaceuticals plc	www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Sir Marc Feldmann, Chairman
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Corporate Finance Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
US Media enquiries	Tel: +1 (323) 646-3249
Lowell Goodman	lowell@corbomitecomms.com

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located at its state-of-the-art research facility in New York City and a wholly-owned Belgian subsidiary, Hemogenyx-Cell SPRL, located in Liège.

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCEASFFFDANFFF